What trials and meta-analyses evaluating RA patients have used health-related quality of life (HRQoL) for assessing patient outcomes? Which agents have been evaluated against this metric?

What trials and meta-analyses evaluating RA patients have used health-related quality of life (HRQoL) for assessing patient outcomes? Which agents have been evaluated against this metric?

What trials and meta-analyses evaluating RA patients have used health-related quality of life (HRQoL) as a metric for assessing patient outcomes? Which agents, including IL-6 inhibitors, have been evaluated against this metric, and what are the findings?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Professor Tom Huizinga, MD, PhD

Professor Tom Huizinga, MD, PhD

Head, Department of Rheumatology
Leiden University Medical Center
Leiden, The Netherlands